Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
11.60
+0.84 (7.81%)
Feb 6, 2026, 4:00 PM EST - Market closed
Biohaven Employees
Biohaven had 256 employees as of December 31, 2024. The number of employees increased by 17 or 7.11% compared to the previous year.
Employees
256
Change (1Y)
17
Growth (1Y)
7.11%
Revenue / Employee
n/a
Profits / Employee
-$3,047,305
Market Cap
1.54B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 493 |
| Agios Pharmaceuticals | 488 |
| uniQure | 209 |
| Relay Therapeutics | 188 |
| Celldex Therapeutics | 186 |
| Monte Rosa Therapeutics | 147 |
| Precigen | 143 |
| Innoviva | 127 |
BHVN News
- 26 days ago - Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 4 weeks ago - Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 - PRNewsWire
- 6 weeks ago - US Stocks Mixed; Biohaven Shares Fall - Benzinga
- 6 weeks ago - Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise - Seeking Alpha
- 6 weeks ago - Biohaven Misses The Mark In Depression Trial, Stock Falls - Benzinga
- 6 weeks ago - Stock Market Today: Dow Jones, S&P 500 Futures Slip After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus - Benzinga
- 6 weeks ago - Biohaven's depression drug fails mid-stage trial, shares fall - Reuters
- 6 weeks ago - Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder - PRNewsWire